In the world of fitness and performance enhancement, Hexarelin and Ipamorelin are two peptides that stand out for their ability to boost growth hormone levels.
And within this mode of action lies their potential to improve muscle growth, recovery, and overall performance.
BUT… their benefits go beyond just physical gains.
In the debate between Hexarelin vs Ipamorelin other aspects of health also come into play.
Further research suggests that both peptides may have neuroprotective effects, which could benefit cognitive function.
They can help regulate metabolism, support tissue repair, and even enhance brain health.
Additionally, their ability to increase bone density can contribute to better overall bone health, which is especially important for older individuals
But despite their similarities, these peptides have unique characteristics that set them apart.
This article will delve into the differences between Hexarelin and Ipamorelin to help you understand their unique qualities and how they can support your fitness, brain health, bone health, and overall well-being.
What is Hexarelin?
Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) composed of six amino acids that works with the pituitary gland to release human growth hormone (HGH).
Researchers from Tulane Medical School discovered the peptide while they were in search of a new way to stimulate growth hormone via the growth hormone secretagogue receptor (GHS-R) pathway without affecting the production/release of other hormones.
As their investigation progressed, benefits such as having higher potency and stability than exogenous ghrelin were also uncovered.
Moreover, since it acts with the CD36 receptor, Hexarelin provides cardio-protective benefits.
Bodybuilders also love this peptide because it can help them pack on muscle or shred unwanted fat.
What is Ipamorelin?
Ipamorelin is a five-amino-acid growth hormone-releasing peptide (GHRP), a.k.a. growth hormone secretagogue (GHS), that mimics the release of growth hormone and the hunger hormone ghrelin.
Unlike Hexarelin, it works by acting with the pituitary gland to effectively release growth hormone without affecting other hormones such as cortisol or adrenocorticotropic hormone (ACTH).
This makes Ipamorelin a safe and effective peptide for anti-aging, muscle growth, enhanced physical performance, and growth hormone regulation.
Moreover, it has a longer half-life than other peptides and can provide a more potent effect.
Hexarelin and Ipamorelin Mechanisms of Action
Hexarelin, just like ghrelin, acts with the pituitary gland to activate and produce growth hormone, but can also lead to the elevation of cortisol and prolactin.
On the other hand, as just stated, Ipamorelin works with the pituitary gland to boost growth hormone levels without affecting the body’s levels of other hormones.
Similarities Between Ipamorelin and Hexarelin
Both Ipamorelin and Hexarelin stimulate the body’s natural production and release of growth hormone (GH).
They work synergistically with growth hormone-releasing hormone (GHRH), resulting in a boost in plasma GH levels even at low doses.
Both peptides also work best with sex hormones such as testosterone, thereby increasing the GH-elevating effects of growth hormone secretagogue receptor (GHS-R) agonists.
And they also exhibit partial and reversible tachyphylaxis, which means their ability to release more growth hormone will improve with consistent and long-term use.
However, both of them have limited human studies and the majority of what we know about them is derived from published animal studies.
Despite that, a growing number of athletic individuals are interested in using Hexarelin and Ipamorelin — and have used them — to improve their health and appearance.
Mechanism of Action
Hexarelin targets the CD-36 and GHSR-1a receptors while Ipamorelin only acts on GHSR-1a, which has no interaction with other hormone receptors and results in a better side effect profile.
(NOTE: GHSR-1 is a ghrelin receptor, as it is bound by ghrelin)
Once bounded, Ipamorelin triggers a biochemical cascade that releases growth hormone from the pituitary gland into the bloodstream.
While Hexarelin also helps trigger GH release, it can also stimulate other hormone pathways such as prolactin and cortisol, influencing the peptide’s effectiveness and side effects.
“To clarify these points, in 6 normal young adults (22-27 yr) we studied the GH, PRL, ACTH and cortisol responses to 1 and 2 micrograms/kg i.v. GHRP-2 and HEX comparing them with that after 1 micrograms/kg i.v. GHRH and 400 micrograms i.v. TRH + 2 micrograms/kg i.v. hCRH.
The Gh responses to 2 micrograms/kg i.v. GHRP-2 or HEX, compared with those to 1 microgram/kg GHRH, were also studied in 6 normal elderly subjects (66-73 yr). In young adults 1 microgram/kg i.v. GHRP-2 and HEX induced a similar, strong GH response, which was higher (p < 0.05) than that of GHRH.
The administration of 2.0 micrograms/kg i.v. GHRP-2 and HEX again elicited a similar GH response, which was higher (p < 0.05) than that after the 1.0 microgram/kg dose. In elderly subjects, the GH those in young subjects. In young adults, the PRL responses to all doses of GHRP-2 or HEX were similar, and lower (p < 0.01) responses were similar to those to hCRH.
In conclusion, our results demonstrate that, in man, GHRP-2 and HEX have similar, 2 and HEX is not fully specific, as they induce similar increases in PRL, ACTH and cortisol levels. The PRL-releasing activity of GHRPs is lower than that of TRH while their ACTH/cortisol-releasing activity is similar to that of hCRH.”
CD-36 receptors, which are usually found in fat cells, immune cells, and liver tissue, promote cardiovascular benefits upon binding to Hexarelin.
Promoting Better Health
To sum up the primary differences in health benefits within a single sentence: Hexarelin supports heart health while Ipamorelin promotes bone growth and muscle release.
Hexarelin has been shown in studies to help patients recover from heart-related surgeries like cardiac bypasses while lowering the risk of hypertension, minimizing the risk of cardiac tissue scarring, and lowering one’sresting heart rate.
Ipamorelin, on the other hand, is mainly used to support bone growth and bone mineral density, especially in people with osteoporosis and bone injuries.
Hexarelin vs Ipamorelin Benefits
Hexarelin and Ipamorelin function in similar ways, but they also have distinct differences with respect to their proven health outcomes.
Growth Hormone Secretion and Body Composition
Both peptides play a pivotal role in growth hormone secretion and body composition.
As ghrelin derivatives, Hexarelin and ipamorelin can help promote lean body mass while reducing adipose tissue.
Yet as emphasized earlier, the former comes at the cost of an increase in cortisol levels and other hunger hormones.
Ipamorelin supports healthy levels of growth hormone release without affecting cortisol levels, making it a safer choice to achieve your fat loss and muscle goals with few to no side effects at all.
This has been shown in a study published in the Journal of Scientific Reports, where rat models of cachexia given Hexarelin regulated their muscle cell health by controlling the mitochondrial function and calcium flow.
Either peptide helps your muscle cells utilize energy more efficiently:
“Chemotherapy can cause cachexia, which consists of weight loss associated with muscle atrophy.
By using a rat model of cisplatin-induced cachexia, we here characterized the mitochondrial homeostasis in tibialis anterior cachectic muscle and evaluated the potential beneficial effects of the growth hormone secretagogues (GHS) hexarelin and JMV2894 in this setting.
We found that cisplatin treatment caused a decrease in mitochondrial biogenesis (PGC-1α, NRF-1, TFAM, mtDNA, ND1), mitochondrial mass (Porin and Citrate synthase activity) and fusion index (MFN2, Drp1), together with changes in the expression of autophagy-related genes (AKT/FoxO pathway, Atg1, Beclin1, LC3AII, p62) and enhanced ROS production (PRX III, MnSOD).
Importantly, JMV2894 and hexarelin are capable to antagonize this chemotherapy-induced mitochondrial dysfunction.
Thus, our findings reveal a key-role played by mitochondria in the mechanism responsible for GHS beneficial effects in skeletal muscle, strongly indicating that targeting mitochondrial dysfunction might be a promising area of research in developing therapeutic strategies to prevent or limit muscle wasting in cachexia.”
Ipamorelin also supports nitrogen balance by minimizing nitrogen wasting in the liver:
“Five groups of rats were included: (1) free-fed controls (2) pair-fed controls (3) prednisolone (delcortol, 4 mg × kg−1 × day−1) (4) prednisolone and GH (1 mg × kg−1 × day−1) (5) prednisolone and Ipamorelin (0.5 mg × kg−1 × day−1).
After seven days the hepatic capacity of urea-N synthesis (CUNS) was determined in parallel with measurements of liver mRNA levels of urea cycle enzymes, whole-body N-balance, and N-contents of various organs.
Compared to pair-fed controls, prednisolone increased CUNS (p < 0.01) as well as the expression of urea cycle genes (p < 0.01), and decreased N-balance (p < 0.01) as well as organ N-contents (p < 0.05). Compared to prednisolone-treated animals, co-administration of GH reduced CUNS by 33% (p < 0.01), normalized urea cycle gene expression, improved N-balance 2.5-fold, and normalized or improved organ N-contents.
In prednisolone-treated rats, Ipamorelin reduced CUNS by 20% (p < 0.05), decreased the expression of urea cycle enzymes, neutralized N-balance, and normalized or improved organ N-contents.”
The unique mechanisms of either peptide and their effects on the growth hormone axis can help you build muscle via boosting growth hormone and insulin-like growth factor 1 (IGF-1) production.
Bone Health
When it comes to bone health, both Hexarelin and Ipamorelin can support bone mineral density and strengthen the skeletal system.
As a growth hormone secretagogue, Ipamorelin helps stimulate the body’s natural growth hormone production, which again is important in supporting and improving bone health.
In a study in the Journal of Endocrinology, rats given ipamorelin had a four-fold increase in bone deposition and boosted bone mineral density:
“Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
The animals were followed in vivo by dual X-ray absorptiometry (DXA) measurements every 4th week.
After the animals were killed, femurs were analyzed in vitro by mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans.
After this, excised femurs and vertebrae L6 were analyzed by the use of Archimedes’ principle and by determinations of ash weights. All treatments increased body weight and total tibial and vertebral BMC measured by DXA in vivo compared with vehicle-treated controls.
However, the total BMC corrected for the increase in body weight (total BMC:body weight ratio) was unaffected.
Tibial area bone mineral density (BMD, BMC/area) was increased, but total and vertebral area BMDs were unchanged.
The pQCT measurements in vitro revealed that the increase in the cortical BMC was due to an increased cross-sectional bone area, whereas the cortical volumetric BMD was unchanged.
Femur and vertebra L6 volumes were increased but no effect was seen on the volumetric BMDs as measured by Archimedes’ principle.
Ash weight was increased by all treatments, but the mineral concentration was unchanged. We conclude that treatment of adult female rats with the GHSs ipamorelin and GHRP-6 increases BMC as measured by DXA in vivo.
The results of in vitro measurements using pQCT and Archimedes’ principle, in addition to ash weight determinations, show that the increases in cortical and total BMC were due to increased growth of the bones with increased bone dimensions, whereas the volumetric BMD was unchanged.”
Similarly, Hexarelin led to improved bone mineral content and bone area at the lumbar vertebrae in intact and ovariectomized rats, as shown in a study published in the European Journal of Endocrinology.
“HEXA was administered for 60 days (50 microg/kg s.c. twice a day) to intact and ovariectomized (OVX) 11-month-old female rats and changes in bone parameters were evaluated concerning those of the same rats under baseline conditions and with those of control rats (intact and OVX) administered isovolumetric amounts of physiological saline.
Serum total alkaline phosphatase (ALP) and urinary deoxypyridinoline (Dpd) were measured before and at various times during HEXA treatment. Bone mineral content (BMC) and density of lumbar vertebrae and femoral mid-diaphyses were measured by dual energy X-ray absorptiometry before and after treatment.
In all groups, serum IGF-I levels were determined before and during treatment and the GH secretory response to HEXA was assessed at the end of the experiment.
In intact rats, HEXA did not modify Dpd urinary excretion, induced a trend toward an increase of serum ALP activity and significantly increased BMC (+6.5%) and bone area (+4.1%) only at lumbar vertebrae.
In OVX rats, HEXA did not modify the OVX-induced increase in bone turnover markers (Dpd and ALP) and did not affect the OVX-induced vertebral bone loss, but significantly increased BMC (+7.2%) and bone area (+5.3%) at femoral mid-diaphyses. HEXA significantly increased serum IGF-I levels at day 14, but not at day 60, in both intact and OVX rats, whereas the GH secretory response to HEXA was higher in the former than in the latter.”
Cardiovascular Health
Unlike Ipamorelin, Hexarelin has cardioprotective qualities due to its CD-36 receptor binding properties.
In a study published in the International Heart Journal, Hexarelin administration helped protect the heart cells of mice from injury by stopping programmed cell death.
What’s most notable is these mice were shown to have improved heart function after being subjected to simulated cardiac ischemia:
“Hexarelin, a synthetic growth hormone-releasing peptide, has been proven to possess cardioprotective actions through its binding to the growth hormone secretagogue receptor (GHSR) 1a and the non-GHSR receptor CD36. However, its effect on myocardial ischemia/reperfusion (I/R) injury has not been fully clarified in vivo.
In vivo hearts of male SD rats underwent 30 minutes of ischemia by left coronary artery ligation followed by reperfusion.
The rats were then treated subcutaneously twice daily with hexarelin [100 μg/kg·day], ghrelin [400 μg/ kg·day], or saline for 7 days.
Echocardiography, malondialdehyde detection, and histochemical staining were performed after treatment.
In addition, Western blot was used to examine the expression levels of IL-1β, IL-1Ra, and IL-1RI. Our study showed that hexarelin treatment improved cardiac systolic function, decreased malondialdehyde production, and increased the number of surviving cardiomyocytes.
The beneficial effects of hexarelin treatment were slightly superior to those of equimolar ghrelin treatment.
We meanwhile confirmed that hexarelin induced down-regulation of IL-1β expression and up-regulation of IL-1Ra expression in I/R myocardium, which could be neutralized by the GHSR antagonist [D-Lys3]-growth hormone releasing peptide-6 ([D-Lys3]-GHRP-6).
These findings suggest that hexarelin protects in vivo cardiomyocytes from I/R injury partly by modification of the IL-1 signaling pathway through the activation of cardiac GHSR1a receptors.”
Apart from supporting the survival of heart muscle cells, the peptide Hexarelin may protect the heart from the long-term effects of oxidative stress, especially for people with a past history heart attacks or any cardiac injuries.
This helps prevent/reduce harmful cardiac remodeling or pathological changes.
Moreover, Hexarelin has been shown to improve the function of the sympathetic nervous system in mice with prior heart injury.
Instead of targeting sympathetic activation, it shifts the biological environment toward parasympathetic activation, thus helping lower blood pressure and heart rate.
Mice that were given Hexarelin were shown to have reductions in cardiac scar formation after injury, as evidenced in a study published in the Journal of Psychological Reports:
“Ischemic heart disease (IHD) is a leading cause of morbidity and mortality worldwide. Growth hormone secretagogues (GHS) have been shown to improve cardiac function in models of IHD. This study determined whether hexarelin (HEX), a synthetic GHS, preserves cardiac function and morphology in a mouse model of myocardial infarction (MI).
MI was induced by ligation of the left descending coronary artery in C57BL/6J mice followed by vehicle (VEH; n = 10) or HEX (0.3 mg/kg/day; n = 11) administration for 21 days.
MI‐injured and sham mice (treated with VEH; n = 6 or HEX; n = 5) underwent magnetic resonance imaging for measurement of left ventricular (LV) function, mass and infarct size at 24 h and 14 days post‐MI.
MI‐HEX mice displayed a significant improvement (P < 0.05) in LV function compared with MI‐VEH mice after 14 days treatment. A significant decrease in LV mass, interstitial collagen and collagen concentration was demonstrated with chronic HEX treatment (for 21 days), accompanied by a decrease in TGF‐β1 expression, myofibroblast differentiation and an increase in collagen‐degrading MMP‐13 expression levels.
Furthermore, heart rate variability analysis demonstrated that HEX treatment shifted the balance of autonomic nervous activity toward a parasympathetic predominance and sympathetic downregulation.
This was combined with a HEX‐dependent decrease in troponin‐I, IL‐1β and TNF‐α levels suggestive of amelioration of cardiomyocyte injury.
These results demonstrate that GHS may preserve ventricular function, reduce inflammation and favorably remodel the process of fibrotic healing in a mouse model of MI and hold the potential for translational application to patients suffering from MI.”
On the other hand, patients who had heart failure and were given Ipamorelin improved their heart muscle contractions (likely through boosting their levels of IGF-1):
“During follow-up (mean, 5.2 years), 56 participants (35 women) developed congestive heart failure.
In multivariable Cox regression models adjusting for established risk factors at baseline, there was a 27% decrease in risk for heart failure for every 1 standard deviation increment in log IGF-I.
Individuals with serum IGF-I level at or above the median value (140 g/L) had half the risk for heart failure (hazard ratio, 0.49 [95% CI, 0.26 to 0.92]) of those with serum IGF-I levels below the median. These comparisons were maintained in analyses adjusting for the occurrence of a myocardial infarction on follow-up.”
Memory Formation
Many people are unaware that ghrelin has a notable impact on memory.
This was first witnessed thousands of years ago when having calorie-rich food was linked to the formation of pleasurable memories while poisonous foods were associated with bad memories.
Clearly, our ancestors’ ability to source good food was useful for survival.
In today’s world, researchers are curious if ghrelin and its analogs (i.e. Hexarelin and Ipamorelin) can support memory formation and neurogenesis.
They tested this hypothesis in mice, which showed that activating growth hormone secretagogue receptors could boost the connections between neurons and thereby strengthen long-term dendrite spine density.
Specifically, it was shown that Hexarelin promotes neurogenesis in the dentate gyrus and subgranular zone of the hippocampus, which is responsible for storing existing memories and creating new memories.
According to a study by Growth Hormone & IGF Research, this happens because Hexarelin promotes the survival and proliferation of neuron progenitor cells:
“In the present study, 10-day-old male mice received 6Gy cranial IR. Non-irradiated sham animals were used as controls.
We treated one group of irradiated and one sham group with hexarelin (100microg/kg/day) for 28days and used immunohistochemical labeling of bromo-deoxy uridine (BrdU) and phospho-histone H3 of the granular cell layer of the DG to evaluate proliferation and cell survival after IR at postnatal day ten.
Our results show that hexarelin significantly increased the number of BrdU-positive cells in the granule cell layer by approximately 50% compared to controls”
On the other hand, patients with cognitive impairment who were given growth hormone secretagogues such as Ipamorelin saw a reduced age-related decline in cognitive function:
“Thirty adults (17 with mild cognitive impairment [MCI]), ranging in age from 55 to 87 years, were enrolled and completed the study.
Participants self-administered daily subcutaneous injections of tesamorelin (Theratechnologies Inc), a stabilized analog of human GHRH (1 mg/d), or a placebo 30 minutes before bedtime for 20 weeks.
At baseline and weeks 10 and 20, participants underwent brain magnetic resonance imaging and spectroscopy protocols and cognitive testing and provided blood samples after fasting. Participants also underwent glucose tolerance tests before and after intervention.
Brain levels of glutamate, inhibitory transmitters γ-aminobutyric acid (GABA) and N-acetylaspartylglutamate (NAAG), and myoinositol (MI), an osmolyte linked to Alzheimer’s disease in humans, were measured in three 2 × 2 × 2-cm3 left-sided brain regions (dorsolateral frontal, posterior cingulate, and posterior parietal).
Glutamate, GABA, and MI levels were expressed as ratios to creatine plus phosphocreatine, and NAAG was expressed as a ratio to N-acetylaspartate.
After 20 weeks of GHRH administration, GABA levels were increased in all brain regions (P < .04), NAAG levels were increased (P = .03) in the dorsolateral frontal cortex, and MI levels were decreased in the posterior cingulate (P = .002).
These effects were similar in adults with MCI and older adults with normal cognitive function.
No changes in the brain levels of glutamate were observed.
In the posterior cingulate, treatment-related changes in serum insulin-like growth factor 1 were positively correlated with changes in GABA (r = 0.47; P = .001) and tended to be negatively correlated with MI (r = −0.34; P = .06).
Consistent with the results of the parent trial, a favorable treatment effect on cognition was observed in substudy participants (P = .03). No significant associations were observed between treatment-related changes in neurochemical and cognitive outcomes.
Glucose homeostasis in the periphery was not reliably affected by GHRH administration and did not account for treatment neurochemical effects.
Twenty weeks of GHRH administration increased GABA levels in all 3 brain regions, increased NAAG levels in the frontal cortex, and decreased MI levels in the posterior cingulate.”
Anti-Aging Effects
Neither Ipamorelin nor Hexarelin has been directly investigated for their anti-aging properties.
However, both peptides increase boost growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels (which naturally decline with age).
Therefore, it follows that doing so may help minimize the signs of aging.
This has been shown in a study where animals given Hexarelin or Ipamorelin were able to function better in their old age:
“GH secretagogues present a tool for furthering our understanding of the control of GH secretion, as well as a unique therapeutic opportunity. These compounds activate the receptors of a putative endogenous ligand in the hypothalamus and pituitary.
Acting as functional somatostatin antagonists, GH secretagogues potentiate the actions of GHRH on GH secretion, enhancing pulsatile GH secretion.
The clinical target of the elderly population presents significant challenges to drug development.
Age-related musculoskeletal impairment as a result of muscle wasting (sarcopenia) is not well recognized as a clinical syndrome. In addition, given the inherent day-to-day variability in function in the “frail” target population as well as the presence of a host of concomitant conditions, the appropriate patient population to be studied remains to be defined, and demonstration of clinically meaningful efficacy may be difficult.
It is not clear whether it will be useful to restore to young levels the activity of the GHIGF-I axis in aging.
Nevertheless, if beneficial effects on strength, similar to those demonstrated with GH79 can be shown, GH secretagogues could provide a well-tolerated clinical approach for treating or preventing sarcopenia, and perhaps, even forestall the inevitability of age-associated decline in function and independence.”
The decrease in GH/IGF-1 levels is thought to arise from insufficient stimulation, indicating a “use it or lose it” dilemma.
They become dormant as we age; thus, the use of Ipamorelin and Hexarelin can stimulate, rejuvenate, and jumpstart the GH/IGF-1 axis to provide their observed anti-aging benefits:
“Two groups of male Wistar rats were studied: young adult (3 mo) and old (24 mo).
Hypothalamic growth hormone-releasing hormone (GHRH) mRNA and immunoreactive (IR) GHRH dramatically decreased (P < 0.01 and P < 0.001) in the old rats, as did median eminence IR-GHRH.
Decreases of hypothalamic IR-somatostatin (SS; P < 0.001) and SS mRNA (P < 0.01) and median eminence IR-SS were found in old rats as were GHS receptor and IGF-I mRNA (P < 0.01 and P < 0.05).
Hypothalamic IGF-I receptor mRNA and protein were unmodified. Both young and old pituitary cells, cultured alone or cocultured with fetal hypothalamic cells, responded to ghrelin. Only in the presence of fetal hypothalamic cells did ghrelin elevate the age-related decrease of GH secretion to within the normal adult range.
In old rats, growth hormone-releasing peptide-6 returned the levels of GH and IGF-I secretion and liver IGF-I mRNA and partially restored the lower pituitary IR-GH and GH mRNA levels to those of young untreated rats.
These results suggest that the aging GH decline may result from decreased GHRH function rather than from increased SS action.
The reduction of hypothalamic GHS-R gene expression might impair the action of ghrelin on GH release. The role of IGF-I is not altered. The aging GH/IGF-I axis decline could be rejuvenated by GHS treatment.”
Side Effects of Hexarelin and Ipamorelin
Hexarelin and Ipamorelin are safe to use but are not entirely free of side effects.
Frequent Hexarelin use may lead to feeling hungrier, retaining more water, or experiencing a tingling sensation in your hands or feet.
(And again, using it for a long time could also raise your cortisol and prolactin levels)
Ipamorelin, on the other hand, tends to have a milder side effect profile.
You might not feel as hungry or bloated, but headaches, dizziness, and a reaction at the site of injection have been reported (although these rarely happen in experienced users).
Just make sure to follow my recommended dosage and timeline for use to avoid the risk of overdose.
Bioavailability of Ipamorelin vs Hexarelin
Ipamorelin and Hexarelin are administered via subcutaneous injection.
Both peptides are sold in powder form and need to be reconstituted before injecting.
Hexarelin can also be used through the nose, but nasal sprays only have 5% bioavailability compared to 77% for subcutaneous injections.
Therefore, if you want to use Hexarelin as a nasal spray, you have to take a higher dosage (which I DO NOT recommend).
Ipamorelin can also be used intranasally, but this also isn’t recommended as it can be metabolized in the gastrointestinal tract before it even reaches GHS-Rs and this will lower its potency and effectiveness.
Dosage Guidelines for Ipamorelin and Hexarelin
If you’re looking to use the peptides Hexarelin and Ipamorelin via subcutaneous injection, their dosing protocols can be found below.
Hexarelin can be used 2-3x daily at 100 mcg per dosage for up to 16 weeks to boost your growth hormone levels.
To experience its muscle-building, bone health, cardiovascular, and brain health benefits, you can use it for a single 12 to 16-week cycle.
Once you complete the cycle, take a 25 to 30-day break and then start another cycle.
Ipamorelin is best used once a day at approximately 200-500 mcg per dose.
You can use the peptide for 12 weeks straight and rest for 3 months before using Ipamorelin again for an additional cycle.
Jay’s Closing Thoughts
Hexarelin is ultimately the inferior peptide due to its worse side effect profile and less potent GH stimulation.
In almost every case, Ipamorelin is the better choice and is far more extensively used by tens of thousands of biohackers like myself.
There couldn’t possibly be a more straightforward conclusion in this comparison between the two peptides.
Ipamorelin vs Hexarelin: Which Peptide Should You Choose?
Both ipamorelin and Hexarelin are safe and effective peptides to improve your overall well-being.
The choice between which of the two is best for you ultimately depends on your preferences and needs.
Hexarelin is known for its potency and rapid HGH increase, but it can also lead to elevated cortisol and prolactin levels while potentially causing unwanted side effects.
On the other hand, Ipamorelin is considered a safer option, offering a more controlled release of HGH with no impact on cortisol and prolactin levels.
Eihter way, the decision should be made based on your tolerance to potential side effects and desired outcomes.
It’s best to consult with your doctor before starting any new regimen to make sure it’s safe for you.
Limitless Life Nootropics, the industry’s only source for third-party-tested products, doesn’t currently have Hexarelin in stock.
However… they DO have some of the best formulations of Ipamorelin on the market.
And don’t forget they offer the BEST deals on both price and peptide purity.
Use code JAY15 at the checkout cart for 15% off!
But before you start injecting these peptides into your body recklessly, make sure you first read the Top 10 Mistakes People Make When Starting Therapeutic Peptides FREE PDF!
Seriously, this short e-book will save you a lot of wasted money and poorly spent time (not to mention preventing you from potential self-inflicted injuries).
And the emails I’ll send you after downloading the book contain an EXCLUSIVE 33% OFF code for my Peptides Demystified Course, so don’t miss out!
Raise Your Vibration To Optimize Your Love Creation!
PS — Want to further enhance your health with peptides Hexarelin and Ipamorelin?
Join me and hundreds of other male and female biohackers in The Fully Optimized Health Private Membership Group to learn how you can use peptides to optimize your health in your 30s and beyond.
We’re excited to discuss biohacking, health, and life optimization through peptide therapy with you.
See you on the other side!
